Lindsay Oneil, APRN
Nurse Practitioner · Omaha, NENPI 1508113929
Payments from drug & device makers
Across 720 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$961
- Gilead$931
- Aimmune Therapeutics, Inc.$848
- plus $4K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 143 | $2,480 |
| Johnson & Johnson | 158 | $2,423 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 53 | $1,121 |
| Takeda Pharmaceuticals U.S.A., Inc. | 37 | $961 |
| Gilead | 58 | $931 |
| Aimmune Therapeutics, Inc. | 5 | $848 |
| Madrigal Pharmaceuticals | 56 | $814 |
| Sanofi | 32 | $744 |
| Regeneron Healthcare Solutions, Inc. | 24 | $419 |
| Lilly USA, LLC | 26 | $408 |
| Phathom Pharmaceuticals, Inc. | 29 | $255 |
| Ardelyx, Inc. | 27 | $241 |
| QOL Medical, LLC | 12 | $178 |
| Nestle Healthcare Nutrition Inc. | 3 | $165 |
| Intercept Pharmaceuticals, Inc. | 10 | $164 |
| Pfizer | 7 | $154 |
| Amgen | 2 | $137 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Bristol Myers Squibb | 7 | $113 |
| Boehringer Ingelheim | 4 | $92 |
| Celltrion USA Inc. | 4 | $75 |
| Ipsen Biopharmaceuticals, Inc | 3 | $72 |
| Merck | 4 | $63 |
| Novo Nordisk | 3 | $53 |
| Ferring Pharmaceuticals Inc. | 3 | $46 |
| KCI USA, Inc. | 1 | $33 |
| Ironwood Pharmaceuticals, Inc | 2 | $33 |
| UCB, Inc. | 2 | $31 |
| Alnylam Pharmaceuticals Inc. | 2 | $30 |
| AstraZeneca | 1 | $13 |
| Organon | 1 | $6 |
How this compares
$13,227 in reported general payments places this provider in the 95th percentile of 924 nurse practitioner providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nurse practitioner in Omaha
- Kristen HammesOmaha$899K
- Amy MuchowiczOmaha$78K
- Kari CunninghamOmaha$53K
- Laura DonovanOmaha$49K
- Kathleen HealeyOmaha$36K
- Katie RuchOmaha$26K
- Amanda GuggenmosOmaha$23K
- Amy YagerOmaha$15K
- Cara SchiesslerOmaha$14K
- Beverly EverittOmaha$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.